BioXcel Therapeutics is trading 60% down at $0.29 in pre-market after filing for Chapter 11 bankruptcy protection in the United States on August 27, 2026.
- Estimated liabilities: $100 million to $500 million; assets: $10 million to $50 million.
- Quarterly results included a $0.49 adjusted loss per share.
- Broader markets were relatively stable.